Bildkälla: Stockfoto

Egetis Therapeutics secures a US Fast Track Designation (FTD) for Emcitate for MCT8 Deficiency - Redeye

Redeye is encouraged by the news that Egetis Therapeutics has received an FTD from the US Food and Drug Administration (FDA) for its lead candidate Emcitate for the treatment of MCT8 Deficiency.

Redeye is encouraged by the news that Egetis Therapeutics has received an FTD from the US Food and Drug Administration (FDA) for its lead candidate Emcitate for the treatment of MCT8 Deficiency.
Börsvärldens nyhetsbrev
ANNONSER